Postherpetic Neuralgia - Pipeline Insight, 2024

This “Postherpetic Neuralgia - Pipeline Insight, 2024,” report provides comprehensive insights about 12+ companies and 12+ pipeline drugs in Postherpetic Neuralgia pipeline landscape. It covers the pipeline drug profiles, including clinical and nonclinical stage products. It also covers the therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.

Geography Covered

• Global coverage

Postherpetic Neuralgia Understanding

Postherpetic Neuralgia: Overview

Post-herpetic neuralgia (PHN) is defined as a chronic neuropathic pain that persists for three or more months following acute Herpes zoster (shingles) infection. It is a severe painful secondary phase, which may develop three to six months after the resolution of initial phase of Herpes zoster (HZ) infection. Pain has a dermatomal distribution and is confined to same dermatome as the rash. Herpes zoster infection results from activation of the varicella zoster virus (VZV) which remains latent in dorsal root ganglia since the first infection of chickenpox (varicella). Pain frequently precedes Herpes zoster infection (pre-herpetic neuralgia), and outlasts the herpetic rash by some weeks. It is more common in older individuals (develops in up to 75% of patients over 70 years of age) and is less common in individuals younger than fifty years of age. Post-herpetic neuralgia subsides eventually on its own. However, it may make patients suffer for years and may leave a band of anaesthetic skin. It may lead to muscle weakness as well, if it affects major motor nerve. Post-herpetic neuralgia is associated with persistent and, very often, refractory neuropathic pain. The neuralgia is excruciating with superimposed lancinating paresthesias. Pain may be constant or intermittent, aggravated by minor stimulus (allodynia) such as heat or touch, and is worse at night. The agony of pain leads to insomnia, anorexia, and changes in mood (severe depression).

Postherpetic Neuralgia - Pipeline Insight, 2024 report outlays comprehensive insights of present scenario and growth prospects across the indication. A detailed picture of the Postherpetic Neuralgia pipeline landscape is provided which includes the disease overview and Postherpetic Neuralgia treatment guidelines. The assessment part of the report embraces, in depth Postherpetic Neuralgia commercial assessment and clinical assessment of the pipeline products under development. In the report, detailed description of the drug is given which includes mechanism of action of the drug, clinical studies, NDA approvals (if any), and product development activities comprising the technology, Postherpetic Neuralgia collaborations, licensing, mergers and acquisition, funding, designations and other product related details.

Report Highlights

• A better understanding of disease pathogenesis contributing to the development of novel therapeutics for Postherpetic Neuralgia.
• In the coming years, the Postherpetic Neuralgia market is set to change due to the rising awareness of the disease, and incremental healthcare spending across the world; which would expand the size of the market to enable the drug manufacturers to penetrate more into the market.

The companies and academics that are working to assess challenges and seek opportunities that could influence Postherpetic Neuralgia R&D. The therapies under development are focused on novel approaches to treat/improve the disease condition.

• A detailed portfolio of major pharma players who are involved in fueling the Postherpetic Neuralgia treatment market. Several potential therapies for Postherpetic Neuralgia are under investigation. With the expected launch of these emerging therapies, it is expected that there will be a significant impact on the Postherpetic Neuralgia market size in the coming years.
• This in-depth analysis of the pipeline assets (in early-stage, mid-stage and late stage of development for the treatment of Postherpetic Neuralgia) includes therapeutic assessment and comparative analysis. This will support the clients in the decision-making process regarding their therapeutic portfolio by identifying the overall scenario of the research and development activities.

Postherpetic Neuralgia Emerging Drugs Chapters

This segment of the Postherpetic Neuralgia report encloses its detailed analysis of various drugs in different stages of clinical development, including phase II, I, preclinical and Discovery. It also helps to understand clinical trial details, expressive pharmacological action, agreements and collaborations, and the latest news and press releases.

Postherpetic Neuralgia Emerging Drugs

HSK16149: Haisco Pharmaceutical Group HSK16149 is being developed by Haisco Pharmaceutical Group to treat Postherpetic Neuralgia. The company is currently conducting a multicenter, randomized, double-blind, placebo-controlled, 12-week, Phase III study to evaluate the efficacy and safety of HSK16149 capsules in chinease patients with PostherpeticNeuralgia.

LX9211: Lexicon Pharmaceuticals LX9211 is an orally-delivered small molecule compound that we are developing as a treatment for neuropathic pain. Scientists identified the target of LX9211, adapter-associated kinase 1, or AAK1, in a target discovery efforts based on their discovery that mice lacking AAK1 exhibited increased resistance to induced neuropathic pain in preclinical models. LX9211 and another development candidate were discovered by scientists working within Lexicon’s drug discovery alliance with Bristol-Myers Squibb from which Lexicon hold exclusive development and commercialization rights. Currently, it is in Phase II stage of clinical trial evaluation to treat Postherpetic Neuralgia.

Postherpetic Neuralgia: Therapeutic Assessment

This segment of the report provides insights about the different Postherpetic Neuralgia drugs segregated based on following parameters that define the scope of the report, such as:

Major Players in Postherpetic Neuralgia

There are approx. 12+ key companies which are developing the therapies for Postherpetic Neuralgia. The companies which have their Postherpetic Neuralgia drug candidates in the most advanced stage, i.e. phase III include, Haisco Pharmaceutical Group.

Phases

This report covers around 12+ products under different phases of clinical development like

• Late stage products (Phase III)
• Mid-stage products (Phase II)
• Early-stage product (Phase I) along with the details of
• Pre-clinical and Discovery stage candidates
• Discontinued & Inactive candidates

Route of Administration

Postherpetic Neuralgia pipeline report provides the therapeutic assessment of the pipeline drugs by the Route of Administration. Products have been categorized under various ROAs such as

• Inhalation
• Inhalation/Intravenous/Oral
• Intranasal
• Intravenous
• Intravenous/ Subcutaneous
• NA
• Oral
• Oral/intranasal/subcutaneous
• Parenteral
• Subcutaneous

Molecule Type

Products have been categorized under various Molecule types such as

• Antibody
• Antisense oligonucleotides
• Immunotherapy
• Monoclonal antibody
• Peptides
• Protein
• Recombinant protein
• Small molecule
• Stem Cell
• Vaccine

Product Type

Drugs have been categorized under various product types like Mono, Combination and Mono/Combination.

Postherpetic Neuralgia: Pipeline Development Activities

The report provides insights into different therapeutic candidates in phase II, I, preclinical and discovery stage. It also analyses Postherpetic Neuralgia therapeutic drugs key players involved in developing key drugs.

Pipeline Development Activities

The report covers the detailed information of collaborations, acquisition and merger, licensing along with a thorough therapeutic assessment of emerging Postherpetic Neuralgia drugs.

Postherpetic Neuralgia Report Insights

• Postherpetic Neuralgia Pipeline Analysis
• Therapeutic Assessment
• Unmet Needs
• Impact of Drugs

Postherpetic Neuralgia Report Assessment

• Pipeline Product Profiles
• Therapeutic Assessment
• Pipeline Assessment
• Inactive drugs assessment
• Unmet Needs

Key Questions

Current Treatment Scenario and Emerging Therapies:

• How many companies are developing Postherpetic Neuralgia drugs?
• How many Postherpetic Neuralgia drugs are developed by each company?
• How many emerging drugs are in mid-stage, and late-stage of development for the treatment of Postherpetic Neuralgia?
• What are the key collaborations (Industry-Industry, Industry-Academia), Mergers and acquisitions, licensing activities related to the Postherpetic Neuralgia therapeutics?
• What are the recent trends, drug types and novel technologies developed to overcome the limitation of existing therapies?
• What are the clinical studies going on for Postherpetic Neuralgia and their status?
• What are the key designations that have been granted to the emerging drugs?

Key Players

• Haisco Pharmaceutical Group
• Lexicon Pharmaceuticals
• Shanghai SIMR Biotechnology Co., Ltd.
• Flexion Therapeutics
• Medifron DBT
• Oxford Cannabinoid Technologies
• Acasti Pharma
• Clexio Biosciences
• Elorac Biotherapeutics

Key Products

• HSK16149
• LX 9211
• SR419
• TV-45070
• MDR-16523
• AAT 730
• GTX-101
• CLE-400

This product will be delivered within 1-3 business days.